Brostallicin

DB06598InvestigationalSmall molecule

Investigated for use/treatment in solid tumors.

Chemical structure of Brostallicin
Primary indication
Investigated for use/treatment in solid tumors.Curator reviewed
Formula / weight
C30H35BrN12O5 · 723.593 g/mol (avg)

Resolves to

Compound
UNIIRPC6R41K4ICAS203258-60-0ChEMBLCHEMBL1189025
Clinical / RWD
PharmGKBPA166119001
Structure
InChIKeyRXOVOXFAAGIKDQ-UHFFFAOYSA-NSMILESCN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC(NC(=O)C(Br)=C)=CN4C)=CN3C)=CN2C)C=C1C(=O)NCCN=C(N)N

What you can answer from here — as of August 30, 2026

5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Brostallicin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In